Britain and America have forged a landmark bilateral deal that will keep no levies on UK drug shipments being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on drugs through the NHS. This pledge ensures that duties on these key products will stay at zero for a period of 36 months.
This deal is in response to earlier statements to hike tariffs on branded pharmaceutical imports, with figures mentioned up to double the cost.
"This arrangement between the United Kingdom strengthens the international landscape for new treatments and introduces much-needed balance to American-British medicine commerce," a release said.
Economic Impact
Drugs constitute one of the UK's most significant export categories to the America, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period prior to the third quarter, the UK shipped drugs worth £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that period.
"This guarantee secures jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact entails several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped twenty percent.
Industry Background
This agreement follows a long-running row between the drug companies and the UK government over drug pricing and approval rates.
This friction were exacerbated by assertions that American patients were paying several times more for the same drugs than people in the other developed nations.
In recent months, several major manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
